IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Bought by Apollon Wealth Management LLC

Apollon Wealth Management LLC lifted its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 5.2% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,666 shares of the company’s stock after acquiring an additional 328 shares during the quarter. Apollon Wealth Management LLC’s holdings in IDEXX Laboratories were worth $3,248,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Manchester Capital Management LLC lifted its stake in shares of IDEXX Laboratories by 11.9% during the fourth quarter. Manchester Capital Management LLC now owns 188 shares of the company’s stock worth $104,000 after purchasing an additional 20 shares in the last quarter. Atomi Financial Group Inc. raised its stake in shares of IDEXX Laboratories by 3.4% during the first quarter. Atomi Financial Group Inc. now owns 637 shares of the company’s stock valued at $344,000 after purchasing an additional 21 shares during the period. Ballentine Partners LLC raised its stake in shares of IDEXX Laboratories by 1.9% during the first quarter. Ballentine Partners LLC now owns 1,188 shares of the company’s stock valued at $641,000 after purchasing an additional 22 shares during the period. Connecticut Wealth Management LLC boosted its stake in shares of IDEXX Laboratories by 3.9% in the fourth quarter. Connecticut Wealth Management LLC now owns 620 shares of the company’s stock valued at $344,000 after purchasing an additional 23 shares during the period. Finally, Kestra Private Wealth Services LLC grew its holdings in IDEXX Laboratories by 3.0% during the 4th quarter. Kestra Private Wealth Services LLC now owns 799 shares of the company’s stock valued at $443,000 after purchasing an additional 23 shares in the last quarter. 87.84% of the stock is owned by hedge funds and other institutional investors.

IDEXX Laboratories Stock Performance

IDXX stock opened at $496.99 on Tuesday. The stock’s 50 day simple moving average is $484.54 and its 200 day simple moving average is $511.31. IDEXX Laboratories, Inc. has a 12-month low of $372.50 and a 12-month high of $583.39. The firm has a market cap of $41.04 billion, a P/E ratio of 48.11, a P/E/G ratio of 3.91 and a beta of 1.32. The company has a current ratio of 1.57, a quick ratio of 1.16 and a debt-to-equity ratio of 0.40.

IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Tuesday, August 6th. The company reported $2.44 earnings per share for the quarter, missing analysts’ consensus estimates of $2.88 by ($0.44). IDEXX Laboratories had a return on equity of 63.66% and a net margin of 23.26%. The business had revenue of $1 billion for the quarter, compared to analyst estimates of $1.01 billion. During the same period last year, the company posted $2.67 earnings per share. The firm’s revenue for the quarter was up 6.4% on a year-over-year basis. As a group, equities research analysts predict that IDEXX Laboratories, Inc. will post 11 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have commented on IDXX. BTIG Research assumed coverage on shares of IDEXX Laboratories in a report on Thursday, July 25th. They issued a “buy” rating and a $580.00 price objective on the stock. Stifel Nicolaus lowered their price objective on IDEXX Laboratories from $520.00 to $510.00 and set a “hold” rating for the company in a research note on Monday, June 24th. StockNews.com lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday, July 10th. Morgan Stanley decreased their price target on shares of IDEXX Laboratories from $620.00 to $596.00 and set an “overweight” rating for the company in a research report on Tuesday, May 14th. Finally, Barclays cut their price target on shares of IDEXX Laboratories from $655.00 to $570.00 and set an “overweight” rating on the stock in a report on Thursday, May 2nd. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $582.25.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.